![Frédéric Grégoire René Sedel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Frédéric Grégoire René Sedel
Gründer bei MedDay Pharmaceuticals SAS
Ursprung des Netzwerks ersten Grades von Frédéric Grégoire René Sedel
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
MedDay Pharmaceuticals SAS
![]() MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France.
10
| Holding Company | Biotechnology | 10 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Frédéric Grégoire René Sedel
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
SANOFI | Pharmaceuticals: Major | Investor Relations Contact | |
IRONWOOD PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Janssen-Cilag Ltd.
![]() Janssen-Cilag Ltd. Pharmaceuticals: MajorHealth Technology Janssen-Cilag Ltd. provides pharmaceutical products and services. It offers medicines that can treat serious health conditions such as schizophrenia, epilepsy, multiple myeloma, and human immunodeficiency virus/acquired immunodeficiency syndrome. The firm's other key areas of activity include pain management, gastroenterology, fungal infections, women’s health, neurology, and anaemia. The company was founded on October 19, 1971 and is headquartered in High Wycombe, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Calliditas Therapeutics Suisse SA
![]() Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Generic | Director/Board Member | |
OXFORD BIOMEDICA PLC | Biotechnology | Director/Board Member | |
ABLYNX | Biotechnology | Director/Board Member | |
ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member | |
DBV TECHNOLOGIES | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
GENFIT | Pharmaceuticals: Major | General Counsel | |
ABIONYX PHARMA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Université Paris Dauphine-PSL | College/University | Graduate Degree | |
Institut National Agronomique Paris-Grignon | College/University | Graduate Degree | |
BPIFrance Investissement SAS
![]() BPIFrance Investissement SAS Investment ManagersFinance BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development. | Investment Managers | Private Equity Investor | |
Innobio 1 FCPI
![]() Innobio 1 FCPI Investment ManagersFinance Innobio FCPI seeks investment opportunities in companies located in France. The fund focuses on innovative technology products and services in the healthcare market. It provides financing for early stage capital requirements and can invest between EUR 3 and EUR 10 million per target. | Investment Managers | Corporate Officer/Principal | |
SENSORION | Pharmaceuticals: Major | Director/Board Member | |
ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member | |
Retrotope, Inc.
![]() Retrotope, Inc. Pharmaceuticals: MajorHealth Technology Retrotope, Inc. operates as clinical-stage pharmaceutical company that develops drugs to treat degenerative diseases. It offers drugs and therapies to treat Parkinson’s, Alzheimer’s, mitochondrial myopathies and retinopathies diseases. The company was founded by Charles R. Cantor, Robert J. Molinari, and Mikhail S. Shchepinov in 2006 and is headquartered in Los Altos, CA. | Pharmaceuticals: Major | Director/Board Member | |
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Université Paris Nanterre | College/University | Graduate Degree | |
Eyevensys SAS
![]() Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Miscellaneous Commercial Services | Director/Board Member | |
PIXIUM VISION | Medical Specialties | Director/Board Member | |
BIOTALYS NV | Chemicals: Agricultural | Director/Board Member | |
GENSIGHT BIOLOGICS S.A. | Pharmaceuticals: Major | General Counsel | |
Asceneuron SA
![]() Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Académie nationale de Pharmacie | Corporate Officer/Principal | ||
Tissium SA
![]() Tissium SA BiotechnologyHealth Technology Tissium SA engages in the development and commercialization of biodegradable sealants and adhesives for invasive surgery. It offers biomimetic wound closure solutions. The company was founded by Bernard J. Gilly, Robert S. Langer, Christophe Bancel, Jeff Karp, Jacques Marescaux, Maria Pereira, and Patrick Houvet in 2013 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
LYSOGENE | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
ESCP Europe Campus London | College/University | Masters Business Admin | |
ENYO Pharma SA
![]() ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France. | Biotechnology | Director/Board Member Director/Board Member | |
CMR Surgical Ltd.
![]() CMR Surgical Ltd. Medical SpecialtiesHealth Technology CMR Surgical Ltd. develops universal robotic system for minimal access surgery. The firm is presently evaluating the ability of the versius system to perform upper GI, gynaecological, colorectal and renal surgery in cadaveric trials. The company was founded by Martin Frost and Mark Slack in January 2014 and is headquartered in Cambridge, the United Kingdom. | Medical Specialties | Director/Board Member | |
INVENTIVA | Biotechnology | Director/Board Member | |
Brainever SAS
![]() Brainever SAS Pharmaceuticals: MajorHealth Technology Brainever SAS manufactures pharmaceutical products. It develops medicines for nervous system diseases. The company was founded on March 31, 2015 and is headquartered in Paris, France. | Pharmaceuticals: Major | Director/Board Member | |
Creabilis SA | Director/Board Member | ||
SparingVision SAS
![]() SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
GENKYOTEX SA. | Pharmaceuticals: Major | Director/Board Member | |
DNA Script SAS
![]() DNA Script SAS Medical SpecialtiesHealth Technology DNA Script engages in the provision of research and development in biotechnology. It manufactures synthetic deoxyribonucleic acid using enzymatic technology. The company was founded by Thomas Ybert, Sylvain Gariel and Xavier Godron in 2014 and is headquartered in Paris, France. | Medical Specialties | Director/Board Member | |
Kymab Group Ltd.
![]() Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Pharmaceuticals: Major | Director/Board Member | |
Universite Paris Cite | College/University | Doctorate Degree | |
Université Paris-Saclay | College/University | Doctorate Degree | |
Noema Pharma AG
![]() Noema Pharma AG BiotechnologyHealth Technology Noema Pharma AG is a biotechnology company, which engages in the development of orphan neurological disorder therapies. It focuses on understanding and meeting patient needs using novel therapies. The company was founded by Luigi Costa and George Garibaldi and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member Founder | |
Tollys
![]() Tollys Hospital/Nursing ManagementHealth Services Tollys is a French company that specializes in developing clinical-grade TLR3 ligands for cancer immunotherapy. The company is based in Lyon, France and was founded by Dominique Rigal. The company's co-founders discovered that TLR3 agonists have the potential to induce direct and immunogenic tumor cell death while sparing normal cells. Tollys has filled a patent for a new family of TLR3 ligands and confirmed freedom to operate. The CEO is Vincent Charlon. | Hospital/Nursing Management | Chairman | |
Moonlake Immunotherapeutics AG
![]() Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Arnout Ploos van Amstel, Jorge Santos da Silva, Kristian Reich. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | Pharmaceuticals: Major | Director/Board Member | |
Burgin & Co. | Chairman | ||
MOONLAKE IMMUNOTHERAPEUTICS | Pharmaceuticals: Major | Director/Board Member | |
Celestial Consulting & Coaching | Founder |
Statistik
International
Frankreich | 30 |
Vereinigtes Königreich | 7 |
Schweiz | 7 |
Vereinigte Staaten | 3 |
Belgien | 3 |
Sektoral
Health Technology | 34 |
Consumer Services | 8 |
Finance | 3 |
Commercial Services | 3 |
Process Industries | 2 |
Operativ
Director/Board Member | 83 |
Independent Dir/Board Member | 26 |
Corporate Officer/Principal | 16 |
Chairman | 14 |
Founder | 7 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Frédéric Grégoire René Sedel
- Unternehmensverbindungen